Urine cytology: appropriate usage maximizes sensitivity and reduces cost

被引:5
作者
Allen, DJ
Challacombe, B
Clovis, JS
Chandra, A
Dasgupta, P
Popert, R
机构
[1] Guys Hosp, Dept Urol, London SE1 9RT, England
[2] Guys Hosp, Dept Cytopathol, London SE1 9RT, England
关键词
urine cytology; audit; clinical governance; inappropriate samples; education;
D O I
10.1111/j.1365-2303.2005.00255.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: Urine cytology is costly because of the skilled manpower required for analysis. Inappropriate requests are a significant drain both financially and on the cytopathologist's time. The present study aimed at identifying the extent and cause of this misuse and reduce it. Methods: An audit of urine cytology usage was undertaken using the hospital results reporting system to identify requests. Patient case notes were then obtained to gain further clinical information. Initially a 2-week period was analysed, following which departmental guidelines for requesting urine cytology were produced and circulated. The audit loop was then closed. Results: Over the initial 2-week period, 117 urine cytology requests were received. Thirty-three per cent were inappropriate, either because they were from patients with benign disease or because of duplication. Following the education programme this number fell to 6%. Expenditure on unnecessary samples thus decreased from 2418 pound to only 310 pound, giving an annual overall saving of 55 pound 000. Conclusion: Significant cost and time savings can be made if urine cytology is sent appropriately. Simple guidelines and staff education are the key to reducing inefficiency. Our findings have implications not just for cytopathology costs but for laboratory and radiology requests in general.
引用
收藏
页码:139 / 142
页数:4
相关论文
共 13 条
  • [1] BASTAKY S, 1984, CANCER, V53, P1555
  • [2] Urine cytology - Is it still the gold standard for screening?
    Brown, FM
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2000, 27 (01) : 25 - +
  • [3] Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer:: Comparison with urinary cytology and BTA test
    Del Nero, A
    Esposito, N
    Currò, A
    Biasoni, D
    Montanari, E
    Mangiarotti, B
    Trinchieri, A
    Zanetti, G
    Serrago, MP
    Pisani, E
    [J]. EUROPEAN UROLOGY, 1999, 35 (02) : 93 - 97
  • [4] Kavaler E, 1998, CANCER, V82, P708, DOI 10.1002/(SICI)1097-0142(19980215)82:4<708::AID-CNCR14>3.0.CO
  • [5] 2-1
  • [6] KOSS LG, 1985, ACTA CYTOL, V29, P810
  • [7] LAMBL WD, 1956, PRAGER VIERTELJ SCHR, V49, P1
  • [8] LAMM DL, 1992, UROL CLIN N AM, V19, P499
  • [9] Lokeshwar VB, 1997, CANCER RES, V57, P773
  • [10] THE CLINICAL-VALUE OF URINARY CYTOLOGY - 12 YEARS OF EXPERIENCE WITH 615 PATIENTS
    MAIER, U
    SIMAK, R
    NEUHOLD, N
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1995, 48 (04) : 314 - 317